你即將離開本站

並前往https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext

a randomised, multicentre, open-label, phase 3 trial - The Lancet

The PD-L1 inhibitor atezolizumab has shown clinical benefit and a tolerable safety profile in metastatic NSCLC and has been approved for use as ...

確定！ 回上一頁

查詢 「Atezolizumab」的人也找了：

  1. atezolizumab自費
    2.
  2. atezolizumab仿單
    3.
  3. atezolizumab中文
    4.
  4. atezolizumab副作用
    5.
  5. atezolizumab價格
    6.
  6. atezolizumab健保
    7.
  7. Atezolizumab
    8.
  8. atezolizumab肺癌
    9.